David Kendall, Zealand Pharma CMO
Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity
SAN ANTONIO — Zealand Pharma, hoping to create the next “foundational” therapy for obesity, detailed more Phase 1 data on its amylin analog that was the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.